Title |
Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes
|
---|---|
Published in |
ClinicoEconomics and Outcomes Research: CEOR, March 2018
|
DOI | 10.2147/ceor.s144208 |
Pubmed ID | |
Authors |
EJ Gibson, N Begum, I Koblbauer, G Dranitsaris, D Liew, P McEwan, AA Tahami Monfared, Y Yuan, A Juarez-Garcia, D Tyas, M Lees |
Abstract |
Economic models in oncology are commonly based on the three-state partitioned survival model (PSM) distinguishing between progression-free and progressive states. However, the heterogeneity of responses observed in immuno-oncology (I-O) suggests that new approaches may be appropriate to reflect disease dynamics meaningfully. This study explored the impact of incorporating immune-specific health states into economic models of I-O therapy. Two variants of the PSM and a Markov model were populated with data from one clinical trial in metastatic melanoma patients. Short-term modeled outcomes were benchmarked to the clinical trial data and a lifetime model horizon provided estimates of life years and quality adjusted life years (QALYs). The PSM-based models produced short-term outcomes closely matching the trial outcomes. Adding health states generated increased QALYs while providing a more granular representation of outcomes for decision making. The Markov model gave the greatest level of detail on outcomes but gave short-term results which diverged from those of the trial (overstating year 1 progression-free survival by around 60%). Increased sophistication in the representation of disease dynamics in economic models is desirable when attempting to model treatment response in I-O. However, the assumptions underlying different model structures and the availability of data for health state mapping may be important limiting factors. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Scientists | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 31 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 6 | 19% |
Other | 3 | 10% |
Student > Bachelor | 3 | 10% |
Student > Postgraduate | 2 | 6% |
Student > Ph. D. Student | 2 | 6% |
Other | 4 | 13% |
Unknown | 11 | 35% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 23% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 13% |
Nursing and Health Professions | 2 | 6% |
Biochemistry, Genetics and Molecular Biology | 1 | 3% |
Unspecified | 1 | 3% |
Other | 4 | 13% |
Unknown | 12 | 39% |